Larry D Anderson Jr. MD PhD, FACP

Hematologic Oncology

Professor, Cellular Therapy and Hematologic Malignancies, Director of Myeloma, Waldenstrom's & Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

Join to View Full Profile

5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2661

Summary

Dr. Larry Anderson is a myeloma specialist in Dallas, TX and is affiliated with UT Southwestern Medical Center. He has been in practice over 19 years and specializes in plasma cell disorders. He is experienced in CAR T-Cell therapy, bone marrow transplantation, clinical trials, multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Washington School of MedicineFellowship, Oncology/Bmt, 2003 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
McGovern Medical School at UTHealthClass of 2000

Certifications & Licensure

TX State Medical License 2008 - 2025
WA State Medical License 2003 - 2010
MN State Medical License 2001 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Best Doctors D Magazine, 2021-2024
Texas Super Doctors Texas Monthly Magazine, 2018-2024
Man of the Year Leukemia & Lymphoma Society North Texas, 2015
Who's Who in Healthcare Dallas Business Journal, 2015
Texas Super Doctor Rising Star Texas Monthly, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Join now to see all

Clinical Trials

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
ACTIVE_NOT_RECRUITING
PHASE3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
ACTIVE_NOT_RECRUITING
PHASE3
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Sep 15
Completed
Phase 1
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy Start of enrollment: 2020 Oct 05
ACTIVE_NOT_RECRUITING
PHASE2
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Start of enrollment: 2018 Dec 13
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) Start of enrollment: 2020 May 27
Completed
Phase 1
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Available
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 3
Longterm Follow-up of Subjects Treated With bb2121 Start of enrollment: 2016 Apr 28
Completed
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Start of enrollment: 2024 Feb 15
RECRUITING
PHASE1, PHASE2
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
AVAILABLE
Join now to see all

Publications & Presentations

PubMed

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-05-13
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherap...
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards
Blood Cancer Journal. 2025-05-09
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas.
Naveen Premnath, Yulun Liu, Heather Reves, Urvashi Pandey, Rasmi G Nair
JCO Oncology Practice. 2025-05-01

Journal Articles

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine

Abstracts/Posters

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 ...
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Larry D. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Cagle, Anderson named 2024 Distinguished AlumniMarch 20th, 2025
$Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma$
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple MyelomaMay 19th, 2021
Researchers Uncover Mutated Genes Involved in Lung Cancer; One Affects NonsmokersOctober 24th, 2017
Join now to see all